Birchview Capital’s TherapeuticsMD TXMD Stock Holding History

Birchview Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$18K	–	67
2021 Q4	$18K	Sell	1,000 -1,000	-50%	-$30K	0.01%	67
2021 Q3	$74K	Hold	2,000	–	–	0.05%	63
2021 Q2	$119K	Hold	2,000	–	–	0.07%	61
2021 Q1	$134K	Buy	+2,000	New	+$157K	0.08%	53

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Birchview Capital's TXMD Position: Q1 2022 in Review

Birchview Capital sold out of TherapeuticsMD (TXMD) in Q1 2022, closing a stake of 1,000 shares — an estimated $18K sold.

Birchview Capital first reported a position in TXMD in Q1 2021 and held it in 4 quarters. The position peaked at $134K in Q1 2021. 124 funds tracked by Wall St. Rank hold TXMD as of Q1 2022.

Birchview Capital reported no remaining TherapeuticsMD position as of Q1 2022 after selling out during the quarter.
Birchview Capital sold 1,000 TherapeuticsMD shares in Q1 2022, an estimated $18K.
Birchview Capital first reported a position in TherapeuticsMD in Q1 2021 and held it in 4 quarters.
Birchview Capital's TherapeuticsMD position peaked at $134K in Q1 2021.
124 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2022.

Based on Birchview Capital's 13F filing for Q1 2022, filed 13 May 2022.